DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Emma Hall, Johann S. de Bono et al.|New England Journal of Medicine|2015Cited by 2.2k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Núria Porta et al.|The Lancet Oncology|2019Cited by 643
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquı́n Mateo, Johann S. de Bono, George Seed et al.|Journal of Clinical Investigation|2019Cited by 303
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.Joaquı́n Mateo, Núria Porta, Ursula McGovern et al.|Journal of Clinical Oncology|2019Cited by 45